Vantage Esmo 2020 roundup
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.
Squelgene does a lopsided swap with Jounce
Celgene opts out of Jounce’s Icos agonist ahead of its merger with Bristol-Myers Squibb.
Glaxo adds flesh to its oncology ambitions
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
Smaller groups await Bristol-Myers Squelgene fallout
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
JP Morgan 2019 day three roundup – Abbvie rekindles the takeover flame
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
Esmo 2018 – Adaptimmune gets the wooden spoon
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
